GlassScriptPhysician profile
Nathan Robert Welch
NPI 1801059605
$2,926.25
in general payments reported to CMS, 2019-2025
19 companies · $753 in 2025
The $753 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $246 · 2021: $332 · 2022: $240 · 2023: $474 · 2024: $735 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,942 · Education: $20.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,941.52 |
| Education | $20.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $737.58 | 2022-2025 | Ozurdex, Lumigan, Alphagan P |
| Regeneron Healthcare Solutions, INC. | $631.47 | 2019-2025 | Eylea Hd |
| Alcon Vision LLC | $293.56 | 2021-2025 | Argos, Clareon, Rocklatan |
| Astellas Pharma US INC | $245.03 | 2023-2025 | Izervay |
| Allergan, INC. | $176.70 | 2020-2021 | |
| Genentech USA, INC. | $174.60 | 2022-2025 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $111.39 | 2022-2023 | Syfovre |
| Aerie Pharmaceuticals, INC. | $82.47 | 2020-2021 | |
| Glaukos Corporation | $73.77 | 2025 | Idosetr |
| Rxsight INC | $70.17 | 2021-2023 | Rxsight Injector Cartridge, Rxsight Light Adjustable Lens (Rxlal), Rxsight Light Delivery Device (Ldd) |
| Horizon Therapeutics Plc | $64.32 | 2021 | |
| Sun Pharmaceutical Industries INC. | $50.16 | 2020-2025 | |
| Biotissue Holdings INC. | $46.28 | 2020-2021 | |
| Ani Pharmaceuticals, INC. | $45.33 | 2025 | Iluvien, Yutiq |
| Eyepoint US, INC. | $43.80 | 2021-2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $31.15 | 2024 | Iheezo |
| Alimera Sciences, INC. | $19.52 | 2024 | Iluvien, Yutiq |
| Bausch & Lomb Americas INC. | $16.64 | 2024 | Miebo, Vyzulta |
| Oyster Point Pharma, INC. | $12.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Welch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.